Group 1 - The eye AI and myopia prevention industry has significant growth potential, with Eagle Eye Technology-B (02251) experiencing a stock price increase of 15% in the afternoon trading session, reaching 12 HKD with a trading volume of 8.686 million HKD [1] - The recently published "Consensus on Eye Health Screening and Management for the Population (2024)" emphasizes the critical role of artificial intelligence in assisting diagnosis, highlighting its ability to automatically identify and classify lesions in fundus images, thereby providing reliable diagnostic references for physicians [1] - Eagle Eye Technology is a leader in the global retinal imaging AI field, having developed an integrated AI solution for retinal imaging that can automatically capture retinal photos and accurately identify 55 eye diseases and risks associated with cardiovascular diseases, diabetes, and dementia, providing diagnostic results comparable to expert-level physicians [1] Group 2 - CICC's research report indicates that Eagle Eye Technology focuses on AI-based fundus imaging screening and has integrated software solutions and hardware devices to provide diagnostic and health risk assessment services [2] - Guoyuan International notes that the company has strong product capabilities in early detection and diagnosis of major diseases, and with the rapid expansion of key outlets and user numbers, the company's performance is expected to grow rapidly amid significant opportunities in the medical AI industry [2]
鹰瞳科技-B(02251)午后涨近15% 体检人群眼健康筛查及健康管理专家共识正式发布 眼底AI及近视防控行业空间广阔